| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в лютому 2001 (uk)
- مقالة علمية تنشرت ف 1 فبراير 2001 (ary)
- article scientifique publié en 2001 (fr)
- im Februar 2001 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 2001 (ast)
- artikull shkencor i botuar më 01 shkurt 2001 (sq)
- scientific article published on 01 February 2001 (en)
- գիտական հոդված հրատարակված 2001 թվականի փետրվարի 1-ին (hy)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - Stewart RJ
- Flynn E
- Panigrahy D
|
| rdfs:label
| - Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (en)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (nl)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (sq)
|
| skos:prefLabel
| - Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (en)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (nl)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (sq)
|
| name
| - Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (en)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (nl)
- Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (sq)
|
| author
| |
| author
| |
| title
| |
| title
| - Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1097/00005392-200102000-00095
|
| is about
of | |
| is cites work
of | - SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas
- A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
- Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate
- Metabolic syndrome and urologic diseases
- Vascular endothelial growth factor and angiopoietin are required for prostate regeneration
- Human prostate cancer risk factors
- Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment
- Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches
- Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
- Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.
- The androgen receptor: structure, mutations, and antiandrogens
- Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting
- Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1.
- Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings.
- Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.
- Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer
- Role of vascular endothelial growth factor in prostate cancer.
- Interferon alpha 2a down-regulates VEGF expression through PI3 kinase and MAP kinase signaling pathways.
- Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts
- Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site
- Vascular endothelial growth factor (VEGF) is suppressed in WT1-transfected LNCaP cells.
- Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway
- Biologic agents as adjunctive therapy for prostate cancer: a rationale for use with androgen deprivation
- A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
- Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy
- The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy
- BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
- Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions
- Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
- Increased endothelial progenitor cells and vasculogenic factors in higher-staged arteriovenous malformations
- Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies
- The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
- SNP and Haplotype Analysis of Vascular Endothelial Growth Factor (VEGF) Gene in Lung Cancer Patients of Kashmir
- WITHDRAWN: Single nucleotide polymorphisms, haplotype association and tumour expression of the vascular endothelial growth factor (VEGF) gene with lung carcinoma
- L’IRM du cancer de la prostate : un changement de paradigme
- Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
- The Vav3 oncogene enhances the malignant potential of prostate cancer cells under chronic hypoxia
- Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
- Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia
- Vascular density is highest in the proximal region of the mouse prostate.
- Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration
- Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
- Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells
- Functional Role of WT1 in Prostate Cancer
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)